BLCO Stock Overview
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Bausch + Lomb Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.52 |
| 52 Week High | US$28.96 |
| 52 Week Low | US$18.41 |
| Beta | 0 |
| 1 Month Change | -9.52% |
| 3 Month Change | 4.27% |
| 1 Year Change | -11.05% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| BLCO | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 3.4% | 1.2% | 1.2% |
| 1Y | -11.1% | -25.5% | 6.1% |
Return vs Industry: BLCO exceeded the Canadian Medical Equipment industry which returned -25.5% over the past year.
Return vs Market: BLCO underperformed the Canadian Market which returned 6.1% over the past year.
Price Volatility
| BLCO volatility | |
|---|---|
| BLCO Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 11.5% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BLCO has not had significant price volatility in the past 3 months.
Volatility Over Time: BLCO's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1853 | 13,300 | Brent Saunders | www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Bausch + Lomb Corporation Fundamentals Summary
| BLCO fundamental statistics | |
|---|---|
| Market cap | CA$7.15b |
| Earnings (TTM) | -CA$356.22m |
| Revenue (TTM) | CA$5.68b |
1.3x
P/S Ratio-20.1x
P/E RatioIs BLCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLCO income statement (TTM) | |
|---|---|
| Revenue | US$4.15b |
| Cost of Revenue | US$1.64b |
| Gross Profit | US$2.50b |
| Other Expenses | US$2.76b |
| Earnings | -US$260.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 60.40% |
| Net Profit Margin | -6.27% |
| Debt/Equity Ratio | 65.9% |
How did BLCO perform over the long term?
See historical performance and comparison